Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Jun;34(7):761-763.
doi: 10.1177/09612033251345017. Epub 2025 May 16.

Progressive repigmentation of hypopigmented lesions in discoid lupus erythematosus with anifrolumab: A report of two cases

Margot Hulin  1   2 , Agathe Le Seac'h  1   2 , Léa Jaume  1   2 , Julien Seneschal  3   4 , Katia Boniface  3 , Annick Barbaud  1   2 , Alexis Mathian  5 , Zahir Amoura  5 , François Chasset  1   2   6
Affiliations
Case Reports

Progressive repigmentation of hypopigmented lesions in discoid lupus erythematosus with anifrolumab: A report of two cases

Margot Hulin et al. Lupus. 2025 Jun.

Abstract

We report two cases of patients with refractory discoid lupus erythematosus (DLE) and dark skin phototypes who experienced progressive perifollicular repigmentation of depigmented lesions under anifrolumab therapy, with sustained improvement over 18 months. These observations highlight a potential novel effect of anifrolumab on cicatricial dyspigmentation in DLE. This effect may represent a valuable therapeutic option for DLE-related damage, particularly in patients with darker skin types.

Keywords: Cutaneous lupus; discoid lupus; systemic lupus erythematosus.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interestsThe authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: FC has received grant/research support from AstraZeneca, BMS and GSK; participated in an advisory board for AstraZeneca, GSK, Celgene, Merck, horizon therapeutics and Principabio and received speaking fees and honoraria from AstraZeneca and GSK BMS. AM has received grant/research support from Sobi; participated in advisory board related to lupus for AstraZeneca; received payment for expert testimony for GSK; received support for attending meetings and/or travel from AstraZeneca and GSK; received consulting fees, speaking fees and honoraria from AstraZeneca and GSK. ZA has received grant/research support from GSK, AstraZeneca, Roche, Novartis, Amgen; participated in advisory board related to lupus for GSK, AstraZeneca, Kezar, Amgen, Otsuka; received consulting fees, speaking fees and honoraria from AstraZeneca and GSK. JS received honoraria from AstraZeneca.

Publication types

MeSH terms

Substances

LinkOut - more resources